Ligand Pharmaceuticals Incorporated
NASDAQLigand Pharmaceuticals heads into the final weeks of Q2 with a sharp tension at its centre: the stock is up 20% in a month, directors are cashing out in size, and shorts are quietly rebuilding. The insider selling is the week's most striking signal. Three independent directors — Jason Haas, Jason Aryeh, and John LaMattina — all sold shares between June 10 and June 12, with combined…
Snapshot as of 17 Jun 2026
Ligand Pharmaceuticals heads into the final weeks of Q2 with a sharp tension at its centre: the stock is up 20% in a month, directors are cashing out in size, and shorts are quietly rebuilding. The insider selling is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LGND — free to start on ORTEX.
Sign up for free →Open LGND on ORTEX